<DOC>
	<DOCNO>NCT01550224</DOCNO>
	<brief_summary>The purpose study first determine Temozolomide plus Vorinostat combination control relapse refractory AML determine combination safely take . The study look side effect Temozolomide plus Vorinostat combination whether treatment schedule tolerate .</brief_summary>
	<brief_title>Phase II Temozolomide + Vorinostat Patients With Relapse/Refractory AML</brief_title>
	<detailed_description>The primary endpoint study determine clinical efficacy determine rate morphological complete remission , 2 different treatment regimen temozolomide vorinostat patient AML poor prognostic feature .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<criteria>Female patient childbearing potential negative serum pregnancy test betahCG within 72 hour prior receive first dose vorinostat . Female patient either post menopausal , free menses &gt; 2 year , surgically sterilize willing use 2 adequate barrier method contraception prevent pregnancy agree abstain heterosexual activity throughout study , start Visit 1 . Male patient agree use adequate method contraception duration study 1 month follow come study study completion . Patient , patient 's legal representative , voluntarily agree participate give write informed consent . Patient &gt; =18 year age day sign informed consent . Patient available periodic blood sampling , study related assessment , management treat institution duration study . Patient chemotherapy , radiotherapy , biological therapy within 30 day ( 42 day nitrosoureas mitomycin C ) prior initial dose study drug ( ) recover adverse event due agent administer 30 day earlier , except hydroxyurea . Patient currently participate participate study investigational compound device within 30 day initial dose study drug ( ) . Patient prior treatment within past 30 day HDAC inhibitor ( e.g. , romidepsin ( Depsipeptide ) , NSC630176 , MS 275 , LAQ824 , belinostat ( PXD101 ) , LBH589 , MGCD0103 , CRA024781 , etc ) . Patients receive compound HDAC inhibitorlike activity , valproic acid , antitumor therapy enroll study . Patients receive compounds indication , e.g . valproic acid epilepsy , may enroll 30day washout period . Patients may receive investigational agent . History allergic reaction attribute compound similar chemical biologic composition temozolomide DTIC vorinostat . History gastrointestinal disease significant bowel resection could interfere drug absorption . Uncontrolled intercurrent illness ( defined investigator ) include , limited , ongoing active infection ( HIV , Hepatitis B Hepatitis C ) , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . Prior allogeneic stem cell transplantation within 2 month trial enrollment . Inability swallow tablet . Prior radiation 25 % bone marrow . Pregnancy lactation ( 2 negative pregnancy test two method contraception abstinence require ) . Prior HDAC inhibitor within 30 day initiate trial therapy list . Concomitant radiotherapy , chemotherapy , immunotherapy . Exclusion Criteria Based Medical History Current Medical Status Patient know psychiatric substance abuse disorder would interfere cooperation requirement trial . Patient , time signing informed consent , regular user ( include `` recreational use '' ) illicit drug , substance abuse recent history ( within last year ) drug alcohol abuse . Patient pregnant breast feeding , expect conceive father child within project duration study . Patient `` currently active '' second malignancy , nonmelanoma skin cancer carcinoma situ cervix , enrol . Patients consider `` currently active '' malignancy complete therapy prior malignancy , disease free prior malignancy &gt; 5 year consider physician less 30 % risk relapse . Patient active infection receive intravenous antibiotic , antiviral , antifungal agent within 2 week prior start study drug . Patient uncontrolled intercurrent illness circumstance could limit compliance study , include , limited following : active infection , acute chronic graft versus host disease , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric condition . Patient history current evidence condition , therapy , lab abnormality might confound result study , interfere patient 's participation full duration study best interest patient participate . Patient history gastrointestinal surgery procedure might , opinion investigator , interfere absorption swallow study drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>